QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed non-small cell lung cancer meeting the following criteria:
• * One to 3 brain metastases, meeting the following criteria:
• * No larger than 3 cm
• * Greater than 5 mm from the optic apparatus
• * Not involving the brainstem, pons, medulla, or midbrain
• * Stable systemic disease for the past 3 months
• * Less than 3 months since completion of primary treatment
• Measurable CNS disease as defined by RECIST criteria
• No leptomeningeal disease documented by MRI or cerebrospinal fluid cytologic evaluation
• PATIENT CHARACTERISTICS:
• Life expectancy ≥ 12 weeks
• Karnofsky performance status 60-100%
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 10 g/dL
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST ≤ 3.0 times ULN
• Serum creatinine ≤ 1.5 mg/dL
• Creatinine clearance \> 50 mL/min
• No other malignancy within the past 5 years, except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No concurrent major medical illness or psychiatric impairment that, in the investigator's opinion, would preclude study participation
• No concurrent active infections
• No known HIV positivity
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective nonhormonal contraception during and for 3 months after completion of study treatment
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior complete resection of all brain metastases
• No prior brain radiation therapy
• No prior temozolomide or erlotinib hydrochloride
• No concurrent enzyme-inducing anti-epileptic drugs
• No concurrent recombinant interleukin-11
• No other concurrent anticancer investigational or commercial agents or therapies, including chemotherapy, immunotherapy, hormonal cancer therapy, radiation therapy, or cancer surgery
• No concurrent enrollment on another clinical trial
• Surgery for symptomatic brain lesions prior to radiosurgery allowed